Peripheral blood stem cell transplantation (PBSCT) is an alternative to autologous bone marrow transplantation (ABMT) and is associated with certain advantages over Priming of patients with different PBSC mobilizing regimens leads to an increase by several fold in circulat-ABMT including faster immunohemopoietic recovery.
However, tumor recurrence which is responsible for most ing hematopoietic progenitors in peripheral blood. However, the effect of these mobilizing regimens on of the treatment failures seen with ABMT 3,4 remains a problem with PBSCT 5, 6 as well. Reinfusion of clonogenic lymphoid cells contained within the harvested PBSC population is not well understood. We have studied the tumor cells with the graft 7, 8 and lack of a graft-versusleukemia (GVL) or graft-versus-tumor (GVT) effect against effect of CY and/or G-CSF ؎ IL-2 containing regimens on lymphoid cells, and their capacity to give rise to cytominimal residual disease in the host 9 are possible factors responsible for the higher relapse rate seen with autologous toxic effectors on subsequent in vitro IL-2 activation in a murine model of PBSC mobilization. C57Bl/6 mice transplantation than with allogeneic transplantation. Immunotherapeutic approaches such as activation of bone marwere given CY 100 or 200 mg/kg on day 0 followed 48 h later by G-CSF 125 g/kg twice a day and/or IL-2 row or PBSC with interleukin-2 (IL-2) followed by IL-2 therapy has shown promise in murine models 10 and is cur-60 000 IU twice a day in different schedules. Mice were sacrificed on day 4, 6, 8 and 10 following CY and the rently being investigated in clinical trials by us and others.
11,12
number of hematopoietic progenitors mobilized to the spleens of these mice was assessed by CFC assay and PBSC are usually obtained by cytotoxic chemotherapy or chemotherapy plus myeloid growth factors (GM-CSF or cytotoxicity was evaluated by 4 h 51 Cr release assay against both NK-sensitive (Yak-1), and NK-resistant G-CSF) induced mobilization. 13, 14 Administration of cytotoxic agents and/or growth factors may lead to both quali-(B16, C1498) cell lines after 24 h in vitro IL-2 activation in the presence of 6000 IU/ml of IL-2. Peak numbers of tative and quantitative changes in the lymphoid content of the PBSC population in addition to its effect on myeloid CFC in the splenic PBSC population were seen on day 6 following CY. Administration of CY 200 mg/kg ؉ Gcells. Thus lymphoid cells in the mobilized PBSC population may differ in IL-2 responsiveness, depending upon CSF, the most potent regimen for CFC mobilization, led to a marked decrease in proportion of CD3 + cells in day the mobilizing regimen. There have been several studies in the past evaluating hemopoietic progenitor cell character-6 PBSC as compared to controls (17.7% vs 3.9% ) and was associated with a significant decrease in generation istics of the PBSC induced by different mobilizing regimens, 15 but data regarding lymphoid lineage cells are lackof cytotoxic cells after IL-2 activation. Combining IL-2 to CY ؉ G-CSF prevented the marked loss in cytotoxicing. In addition optimal mobilizing regimens are not well defined, due in part to lack of a suitable animal model. ity associated with this regimen without any decrease in number of CFC mobilized. When IL-2 was combined Systemic therapy with IL-2 has been used to treat different neoplastic states with considerable success in certain with CY without G-CSF, the number of CFC mobilized was comparable to that seen with CY ؉ G-CSF and disorders. 16, 17 In vivo administration of IL-2 leads to activation of lymphoid cells and generation of cytotoxic precurthese CY ؉ IL-2 mobilized PBSC generated potent cytotoxic effectors after in vitro IL-2 activation. Thus sors and effectors. 18, 19 IL-2 administration during mobilization of PBSC could possibly enhance the cytotoxic our results indicate that combining IL-2 with a PBSC mobilizing regimen can avert a decrease in the cytotoxic potential of PBSC. In addition this may have an advantageous effect on hematopoietic progenitor cell content due potential of mobilized cells without compromising the number of hematopoietic progenitors.
to myeloid growth factors secreted by activated lymphocytes and NK cells. −5 m 2-mercaptoethanol, 100 units/ml penicillin and ume of 10 ml. The culture flasks were incubated at 37°C 100 g/ml streptomycin (CM) and cryopreserved in 10% in a 5% CO 2 incubator for 24 h, after which period cells dimethyl sulfoxide (DMSO) and 90% FCS. For cytotoxicity were harvested. After recording cellular recovery, cells assays, cells were allowed to grow in CM for 48 h at 37°C
were used for cytotoxicity and clonogenic assays. in a 5% CO 2 incubator before use.
Cytotoxicity assay PBSC mobilization
A standard 4-h 51
Cr release assay was used to determine the cytolytic activity of cultured PBSC against B16, C1498 For mobilization of PBSC, mice were primed with a protocol modified from Neben et al. 21 On day 0 mice were given and Yak-1 cell targets as described earlier. 22 Briefly, target cells were harvested in the log phase of their growth and CY in a dose of 100 or 200 mg/kg by intraperitoneal injection (i.p.). Forty-eight hours following CY, mice were labeled with Na 2 51 CrO 4 (Amersham, Arlington Heights, IL, USA). 5 × 10 3 target cells/well were incubated with started on either recombinant hG-CSF (Amgen, Thousand Oaks, CA, USA) 125 g/kg twice a day by subcutaneous effector cells at different effector:target (E:T) ratios for 4 h at 37°C in 5% CO 2 . To determine spontaneous and total injection or recombinant human IL-2 (a gift from Chiron, Emeryville, CA, USA) (specific activity 18 × 10 6 IU/mg), release of radioactivity the same number of target cells was incubated with culture medium alone or 0.1 m HCl respect-60 000 IU twice a day i.p. or a combination of both G-CSF and IL-2. In pilot experiments, as has been demonstrated ively. The culture supernatant was harvested with the Skatron Titertek System (Skatron, Lier, Norway) and counted earlier by Neben et al, 21 a higher number of hematopoietic precursors were mobilized to the spleens of these animals in a gamma counter. The percentage lysis was calculated as: as compared to peripheral blood (data not shown). Kinetics of hematopoietic progenitor mobilization to the spleens of (Experimental c.p.m. − spontaneous c.p.m./ primed animals was assessed by enumerating CFC content Maximal c.p.m. − spontaneous c.p.m.) × 100 of the spleens as described below on day 4, 6, 8 and 10 after CY dose. Similar to findings of Neben et al 21 in perAll determinations were made in triplicate and data were calculated as mean ± standard error of mean (s.e.m.). ipheral blood, the peak number of hematopoietic progenitors in the spleens of these animals was seen on day 6 after CY administration and declined over the next 4 days (by Clonogenic assay day 10) in spite of continued G-CSF and/or IL-2 administration. Based on these findings and the feasibility of
The number of hematopoietic progenitors in the mobilized PBSC population or normal splenocytes was assessed by obtaining a sufficient number of cells for further studies, only splenic 'PBSC' were used in subsequent experiments.
enumerating the number of colony-forming cells (CFC) in a clonogenic assay similar to that described earlier 23 for However, on day 6 a rebound increase in the number of PBSC was observed and the number of cells recovered was human cells with the following modifications. Fresh PBSC or those obtained after IL-2 culture were added to semisolid higher than that obtained on day 4 after CY or from normal spleens. Combining IL-2 with the regimen of CY/G-CSF methyl cellulose media (HCC 3230; Stem Cell Tech, Vancouver, Canada) supplemented with erythropoietin (2 U/ml) was not associated with a significant change in the number of cells obtained by CY/G-CSF alone, irrespective of CY and GM-CSF (5 ng/ml), in a cell concentration of 2.5 × 10 4 − 2 × 10 5 cells/ml. One ml cultures were plated in duplicate dose and day of harvest. in 35 mm petri dishes and incubated at 37°C in a humidified atmosphere of 5% CO 2 . The total number of colonies having
Phenotype of lymphoid cells in PBSC mobilized by Ͼ40 cells (CFC) including CFC-granulocyte, macrophage, different regimens CFC-erythroid and CFC-mixed were scored on day 7.
Phenotypic analysis was performed on the PBSC to evaluate the proportion of T cell subsets and NK cells. Flow Statistical analysis cytometric analysis was done sequentially on day 4, 6, 8 and 10 after the CY dose. Results for day 4 and day 10 for Where appropriate, comparison between different groups was made using the Student's t-test. different regimens are shown in Table 1 . A marked decrease in proportion of CD3 + and NK 1.1 + cells was seen when priming was performed by potent mobilizing regimens such as CY + G-CSF Ϯ IL-2. The shifts in phenotype of the cells were evident by day 4. However, the same trend Results of decrease in proportion of these cells was observed over subsequent time points. In contrast to priming by CY + G-PBSC recovery after different priming regimens CSF, CY alone in both doses used was associated with a Total mononuclear cell (PBSC) recovery per spleen was significant increase in relative proportion of CD3 + cells, evaluated 4 or 6 days after CY administration. Results from which was still evident on day 10 after CY dose. This these experiments are shown in Figure 1 . Both doses of observed effect may reflect differential sensitivity of CY (100 mg/kg and 200 mg/kg) were associated with a myeloid vs lymphoid cells to CY. Combination of IL-2 with significant decline in the total number of mononuclear cells CY to mobilize PBSC maintained the proportion of lymph-(PBSC) recovered on day 4 as compared to the number oid cells comparable to that seen in the control sample. obtained from unperturbed spleens. This decrease was seen However, when IL-2 was added to CY + G-CSF, a decrease irrespective of combining CY with G-CSF or G-CSF/IL-2.
in proportion of T and NK cells was still seen. The proportion of cells with the activation marker CD71 increased over time and was especially marked in G-CSF containing regimens.
Cytotoxicity of primed PBSC after in vitro IL-2 activation
Generation of cytotoxic effectors in the PBSC populations obtained by different priming regimens was evaluated by 4 h 51 Cr release assay, after in vitro incubation of the PBSC in the presence of 6000 IU/ml of IL-2. Cytotoxicity was evaluated against the NK-resistant B16 and C1498, and NK-sensitive Yac-1 cell lines. The mobilizing regimen of CY/G-CSF was associated with a significant decrease in cytolytic activity generated in primed PBSC as compared to normal splenocytes, after IL-2 activation. Results are shown in Table 2 . As is evident from Table 2 , this decrease in cytolytic activity was seen against both NK sensitive (Yac-1) and NK-resistant targets (B16, C1498), however this decrease was most marked for the relatively difficult to lyse B16 cell line. higher dose of CY was associated with a decrease in cyto- PBSC were harvested from spleens of mice on day +6 after a single dose of CY 200 mg/kg on day 0 and G-CSF 125 g/kg twice a day from day +2 to +6. A 4 h 51 Cr release assay was performed to determine the cytolytic activity of PBSC/normal splenocytes after 24 h IL-2 activation in vitro. Pooled data (mean ± s.e.m.) from five different experiments are shown and represent % lysis of target cells at an E:T ratio of 50: 1. lytic activity. This decrease in cytotoxicity was observed, whether PBSC were obtained on day 4 or day 6 after CY dose. Similar to the results shown in Figure 2 for C1498, decreased cytotoxicity was also observed against other two in the mobilizing regimen (data not shown).
activation. Mice were primed with either CY 200 mg/kg or 100 mg/kg followed by G-CSF. PBSC were harvested from both groups on day 4 and day 6 and generation of cytotoxic effectors by in vitro IL-2 activation
Duration of priming and cytotoxicity
was evaluated by 51 Cr release assay. Lysis of C1498 at E:T ratio of 50:1 is shown and data represent mean Ϯ s.e.m. of the triplicates from a repIn addition to harvesting PBSC in the recovery phase on resentative of three similar experiments. Difference in cytotoxicity for both day 4 (P Ͻ 0.05) and day 6 (P Ͻ 0.002) was significant. -¼-, Day 4 day 6 after CY dose, PBSC were also harvested on day 4 after CY; --, day 6 after CY.
after CY administration. After IL-2 activation of these day 4 and day 6 PBSC, cytotoxicity was evaluated by 4 h 51 Cr release assay. Results from these experiments are shown in Figure 2 and Table 3 . Irrespective of CY dose (100 mg/kg Effect of G-CSF/IL-2 priming on cytotoxicity vs 200 mg/kg, Figure 2 ), cytotoxicity generated in day 4 PBSC was higher than that observed in day 6 PBSC.
Effect of G-CSF/IL-2 priming on subsequent generation of cytotoxicity is shown in Figure 3 . A decrease in cytotoxicResults for the same mobilizing regimen are compared in Table 3 . As is evident from Table 3 , significantly higher ity of the mobilized PBSC was observed only when G-CSF was combined with CY. Priming with G-CSF alone was cytotoxicity was generated in day 4 PBSC as compared to day 6 PBSC mobilized by CY 200 mg/kg and G-GSF. This not associated with a decrease in cytotoxicity over that seen with unprimed splenocytes and in contrast CY alone led to effect was also seen when IL-2 was included in the mobilizing regimen (data not shown).
an augmentation in the cytotoxic activity of primed PBSC. PBSC were harvested from spleens of mice on day +4 (A) or +6 (B) after a single dose of CY 200 mg/kg on day 0 and G-CSF 125 g/kg twice a Mice were given CY 100 mg/kg on day 0 followed by G-CSF 125 g/kg twice a day alone (group A) or in combination with IL-2 60 000 IU/mouse day from day +2 to day of harvest and were subjected to IL-2 activation for 24 h. A 4 h 51 Cr release assay was performed to determine cytolytic twice a day (group B) from day 2 to 4. Cytolytic activity of PBSC harvested from spleens was assessed against cell lines indicated after 24 h activity of these PBSC against the cell lines indicated. Pooled data (mean 
Effect of duration of priming on number of hematopoietic precursors
In contrast to the decreased cytotoxicity generated in day s.e.m. from three different experiments, P Ͻ 0.01). When IL-2 was combined with the above regimen, the numbers of CFC obtained on day 4 vs day 6 were 308.8 Ϯ 125.8 As shown in Figure 3 , in vivo administration of IL-2 either and 1313.0 Ϯ 74.2 respectively (mean Ϯ s.e.m. from three alone or in combination with CY or CY/G-CSF led to different experiments, P Ͻ 0.01). Similar results were increased cytotoxicity of the PBSC after in vitro culture in obtained when the CY dose was 100 mg/kg or when G-IL-2. When IL-2 was combined with the CY/G-CSF regi-CSF/IL-2 were used alone without CY (data not shown). As men in a dose of 60 000 IU/mice twice a day i.p., it led to the number of PBSC obtained per spleen was also higher on an increase in cytotoxicity, irrespective of the CY dose and day 6 ( Figure 1 ) than on day 4, the increase in the total duration of priming. The effect on day 4 PBSC of combinnumber of clonogenic cells obtained on day 6 per spleen ing IL-2 with CY 100 mg/kg and G-CSF 125 g/kg twice becomes even higher than that shown above for 10 5 a day for 2 days is compared in Table 4 . As is evident plated cells. from the Table, the addition of IL-2 was able to restore the decreased cytotoxicity seen with CY/G-CSF combination.
Effect of CY dose on hematopoietic precursors Hematopoietic progenitors in mobilized PBSC
Priming with a higher dose of CY (200 mg/kg) led to a higher number of CFC in day 6 PBSC. Results from these The hematopoietic reconstituting ability of PBSC mobilized by different regimens, before and after in vitro IL-2 actiexperiments for the mobilizing regimen of CY/G-CSF are shown in Figure 4 . In PBSC harvested on day 6 after a CY the number of CFC compared to obtained by CY alone. Addition of IL-2 to the mobilizing regimen of CY/G-CSF dose of 200 mg/kg, a significantly higher number of CFC were seen than those obtained after 100 mg/kg of CY.
was associated with mild increase in the number of CFC mobilized to the spleen. A comparison of the number of However, this effect was not seen if PBSC were harvested on day 4 after CY. In contrast the number of CFC in day CFC in day 6 PBSC mobilized by CY 200 mg/kg plus G-CSF or G-CSF + IL-2 is shown in Figure 5 . As is evident 4 PBSC was significantly higher in the group receiving the lower dose of CY. Similar results to those shown for CY/Gfrom Figure 5 , addition of IL-2 to a conventional regimen of CY/G-CSF for PBSC mobilization certainly did not have CSF in Figure 4 were obtained if CY alone, CY + IL-2 or CY/G-CSF + IL-2 was used for PBSC mobilization (results a negative effect and had, if any, a positive effect on the number of CFC. not shown), and the higher dose of CY was associated with a higher number of CFC in day 6 PBSC.
We also evaluated the number of hematopoietic precursors present after in vitro activation of PBSC with IL-2. Results for day 6 PBSC mobilized with CY 200 mg/kg and Effect of G-CSF/IL-2 on the number of hematopoietic G-CSF or G-CSF + IL-2 are shown in Figure 5 . A signifiprecursors cant decline in the number of CFC in day 6 PBSC was seen, whether mobilized by CY/G-CSF or CY/G-CSF + ILThough as stated earlier, G-CSF alone led to an increase in hematopoietic precursor cell activity in the spleen by 2. However, no decline in number of CFC was seen after activation of day 4 PBSC irrespective of mobilizing regiseveral fold over baseline, the most potent single stimulus for mobilization of hematopoietic precursors to spleen was men (data not shown). found to be CY in a dose of 200 mg/kg. With this dose of CY alone the number of CFC was Ͼ3-fold higher than that obtained with eight doses of G-CSF alone. However, the combination of G-CSF with CY led to an increase in the Discussion number of CFC over that obtained by the corresponding doses of CY or G-CSF alone. This increase was particularly Current protocols for PBSC mobilization employ either chemotherapy or myeloid growth factors in isolation or in striking, when a lower dose of CY was used and PBSC were harvested on day 4 after CY administration. combination. 13, 14 G-CSF or GM-CSF, the common growth factors used to mobilize PBSC, primarily affect myeloid IL-2 in isolation was found to be a weak stimulus for mobilizing hematopoietic precursors to the spleen. Howlineage cells and their effect, if any, on lymphocytes and NK cell is less well understood. 24, 25 The combination of ever a combination of IL-2 with CY led to an increase in cytotoxic chemotherapeutic agents and myeloid growth fac- tors can lead to qualitative and quantitative changes in ation, the combination of CY and G-CSF led to a marked decrease in induction of cytotoxicity by in vitro IL-2 actilymphoid cells contained in the graft by a direct inhibitory effect on these cells, or merely by a relative decrease in vation. This decrease in cytotoxicity was more marked with the higher CY dose. However, this effect was not seen the proportion of these cells. Lymphoid cells contained in the bone marrow graft play an important role in eradication when CY or G-CSF were used in isolation. On the contrary, PBSC mobilized by CY alone showed higher cytotoxicity of residual tumor by inducing a GVL effect in the setting of allogeneic BMT. 9 In autologous transplantation as well, than unprimed splenocytes, and the result with G-CSF alone was similar to that seen in unprimed splenocytes. a GVL effect can be generated by IL-2 activation of the graft and post-transplant IL-2 therapy.
10 For these reasons, These results can possibly be explained by the marked decrease in the proportion of T and NK cells in PBSC mobit may be critical to maintain activity of the immune cells in the PBSC graft, whether for auto or allogeneic transplanilized by regimens having both CY and G-CSF. In addition to the difference in the content of hematopoietic progenitation.
We have recently shown that PBSC primed by chemotors, noticeable differences were seen in the cytotoxic potential of PBSC harvested on day 4 or day 6 after CY. therapy and myeloid growth factors can be activated to generate anti-tumor cytotoxic effectors by in vitro culture of
As the CFC content of PBSC increased on day 6, a decrease in cytotoxicity was noted. Thus, the mobilizing regimens these cells in the presence of IL-2.
23 These IL-2 activated PBSC, once transplanted back in vivo can possibly mediate associated with a higher yield of CFC in PBSC, led to a decrease in the cytotoxic potential of the PBSC. This most a GVL effect in vivo and this aspect is being further evaluated in clinical trials.
12 However, our results indicate that likely could result from a dilution of the lymphoid content of the PBSC due to excessive mobilization of myeloid lin-PBSC from all tumor bearing patients do not generate potent cytotoxic effectors, particularly patients with metaeage cells, as is suggested by phenotypic analysis on PBSC on different days after CY dose. No decrease in CFC constatic disease. 26 It is possible that the priming regimen for PBSC mobilization also contributes to this decreased cytotent of day 4 PBSC was seen with incubation of these cells in vitro with IL-2 for 24 h (results not shown). However, toxicity seen in these cases. However, as it is difficult to study the effects of different priming regimens and their some decrease in the CFC content of day 6 PBSC was noted after in vitro activation with IL-2 for the same period. effects on lymphoid cells in mobilized PBSC in humans due to a variety of reasons, we have studied this in a This is in contrast to findings reported earlier by us with human PBSC. 23 This discrepancy can be due to the differmurine model.
The systemic administration of IL-2 has been shown to entiation status of precursors in the two PBSC populations.
As results with day 4 PBSC suggest, PBSC harvested early mediate anti-tumor responses in different neoplastic disorders and is currently being studied further in several in the course, which are possibly less differentiated, do not show a decrease in the number of clonogenic cells by trials.
27 These IL-2 induced anti-tumor responses are mediated possibly through the effect of IL-2 on T and NK further in vitro activation. A similar situation may be the case with human cells, which are harvested soon following cells, rendering them directly cytotoxic to the tumor cells or causing the secretion of cytokines which inhibit tumor the WBC nadir.
In vivo priming with IL-2 alone led to a marked increase growth. However, in addition to these effects, IL-2-activated lymphocytes and NK cells secrete several myeloid in the cytotoxicity of PBSC after in vitro IL-2 activation. Combination of IL-2 with other mobilizing regimens was growth factors. 20 Thus the use of IL-2, during the PBSC mobilizing regimen, not only could lead to activation of always able to increase the cytotoxicity over that seen without IL-2. This effect of IL-2 was more pronounced in the lymphoid cells but also could enhance PBSC mobilization. We tested this hypothesis in our present study.
groups where a marked decrease in cytotoxicity was noted with the priming regimen. Thus, the combination of IL-2 In our pilot experiments, as has been reported earlier, 21 we found that hematopoietic progenitors increased in the with CY + G-CSF was able to ameliorate the decrease in cytotoxicity noted in the PBSC of mice primed with this spleens of mice along with those in the peripheral blood. In addition, due to the practical difficulty of getting a sufregimen. In addition to increasing cytotoxicity, a slight effect of IL-2 in increasing CFC content was noted as well. ficient number of peripheral blood PBSC to perform in vitro IL-2 activation and cytotoxicity assays, only splenic monoThis was particularly marked when IL-2 was combined with CY, and in this group, IL-2 led to an increase in the nuclear cells were used in all the experiments as PBSC population. As optimal PBSC mobilization techniques are CFC content to a level comparable to that seen with CY + G-CSF. Previous studies have shown that patients on still not well defined, 15 we also evaluated the hematopoietic progenitor content of the PBSC mobilized by different regi-IL-2 therapy show an increased number of cytotoxic precursors and effectors in the circulation and the lymphoid mens by in vitro assay enumerating myeloid and erythroid clonogenic cells (CFC) in semisolid media.
cells from these patients show enhanced cytotoxicity in vitro. However, short-term use of IL-2 for PBSC mobilizFor PBSC mobilization, a single dose of CY 200 mg/kg was found to be the most potent single factor in terms of ation in our study is not expected to lead to a significant expansion of lymphoid cells, which is supported by pheno-CFC content of PBSC. However a lower dose of CY (100 mg/kg) was found to be less effective than G-CSF alone in typic data on PBSC mobilized by different regimens. Instead, the increase in cytotoxicity observed may be due the dose of 125 g/kg (eight doses). However, when both of these were combined together, the number of CFC mobito qualitative changes such as activation of T and NK cells. Increase in the number of hematopoietic precursors in lized was greater than that mobilized with the corresponding dose of either agent alone. In contrast to CFC mobilizresponse to IL-2 administration may be due to myeloid 
